Skip to main content

Table 2 Mean liver dose (MLD) and proportion of circulating lymphocytes receiving ≥0.5Gy (CL0.5) by intrahepatic locations as a mean for all treatment modalities and beam energies

From: Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study

2. Dependence on tumor location

Tumor location

MLD

CL0.5

Apical

3.1 Gy

18.8%

Basal

3.4 Gy

19.0%

Central

5.3 Gy

31.3%